{"status": "ok", "totalResults": 2, "articles": [{"source": {"id": "engadget", "name": "Engadget"}, "author": "Mariella Moon", "title": "EU reinstates $400 million fine on Intel for blocking sales of competing chips - Engadget", "description": "The European Commission has imposed a \u20ac376.36 million ($400 million) fine on Intel for blocking the sales of devices powered by its competitors' x86 CPUs.", "url": "https://www.engadget.com/eu-reinstates-400-million-fine-on-intel-for-blocking-sales-of-competing-chips-115922364.html", "urlToImage": "https://s.yimg.com/ny/api/res/1.2/nJXqHfyvPYaNjLg.jClM8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03OTQ-/https://s.yimg.com/os/creatr-uploaded-images/2023-09/75b8d740-5939-11ee-b7fb-2010787c68a8", "publishedAt": "2023-09-22T11:59:22Z", "content": "The European Commission has imposed a 376.36 million ($400 million) fine on Intel for blocking the sales of devices powered by its competitors' x86 CPUs. This brings one part of the company's long-ru\u2026 [+2853 chars]"}, {"source": {"id": null, "name": "Astrazeneca.com"}, "author": null, "title": "Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial - AstraZeneca", "description": "", "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/dato-dxd-improved-pfs-in-breast-cancer.html", "urlToImage": "", "publishedAt": "2023-09-22T01:30:00Z", "content": "Positive high-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement for the p\u2026 [+9913 chars]"}]}